Longevity logo

Japan Transcatheter Heart Valve Replacement Market Size and Forecast 2025–2033

A Rapidly Expanding Cardiovascular Innovation Market Driven by Aging Demographics and Advancing Valve Technologies

By Ben TomPublished about a month ago 5 min read

Japan Transcatheter Heart Valve Replacement Market Outlook

According to Renub Research, the Japan Transcatheter Heart Valve Replacement (TAVR) Market is expected to reach US$ 785.78 million by 2033, rising from US$ 327.31 million in 2024. The market will expand at a CAGR of 10.22% from 2025 to 2033, positioning Japan among the fastest-growing global hubs for structural heart innovation.

Japan’s aging population—one of the most elderly in the world—has significantly increased the incidence of valvular heart disorders, particularly aortic stenosis. Combined with strong regulatory backing, next-generation valve approvals, and advanced healthcare infrastructure, these factors are fueling the rapid expansion of the TAVR market nationwide.

The Renub Research report segments the market by Type, Material, End User, City, and provides a comprehensive Company Analysis from 2025 to 2033.

Download Free Sample Report

Japan Transcatheter Heart Valve Replacement Industry Overview

Japan’s TAVR market is in the midst of a transformative decade. As the country confronts rising cases of aortic stenosis in individuals aged 75 years and above, transcatheter valve procedures have emerged as a clinically preferred and economically viable alternative to open-heart surgery.

The shift toward minimally invasive treatment is supported by Japan’s world-class hospitals, accelerated device approvals, and favorable national healthcare reimbursement policies.

Why TAVR is Surging in Japan

Japan’s healthcare ecosystem is uniquely positioned to support high-volume, high-precision structural heart procedures. Key drivers include:

One of the world’s highest life expectancies, increasing demand for minimally invasive therapies.

Rapid adoption of technology-enhanced valves with better deliverability and durability.

Nationwide expansion of hybrid operating rooms that streamline TAVR procedures.

Strong clinical acceptance of TAVR among cardiologists and cardiac surgeons.

Expedited approval pathways by PMDA and MHLW for breakthrough cardiovascular technologies.

Notably, academic centers and national teaching hospitals are playing a pivotal role in validating next-generation balloon-expandable and self-expanding valves, which enhances physician confidence and patient demand.

Key Factors Driving Market Growth

1. Increasing Physician Knowledge and Advanced Training

Japan has made significant progress in building a highly skilled medical workforce capable of performing complex transcatheter procedures. Interventional cardiologists and cardiac surgeons now routinely participate in:

Internationally supervised fellowship programs

AI-enabled virtual simulations

Hands-on cadaver labs

Collaborative case reviews with top U.S. and European cardiac centers

This high level of procedural competency has reduced complications such as vascular access issues and post-implant leaks, enhancing trust among physicians and patients alike. As a result, TAVR is being recommended earlier and more frequently, especially for elderly patients who are not candidates for open-heart surgery.

2. Regulatory Support and Faster Approvals

Japan’s regulatory environment has evolved significantly to support rapid adoption of innovative cardiovascular devices.

Key policy shifts include:

Conditional early approvals for breakthrough heart valve devices

Streamlined pathways for products with strong clinical evidence

“Sakigake Designation,” Japan’s version of priority review

Close oversight of post-market safety to encourage clinician confidence

These changes allow patients to access the latest valve technologies faster while ensuring medical safety remains uncompromised. The PMDA and MHLW’s collaboration with global industry leaders has made Japan one of the most innovation-friendly markets in Asia-Pacific.

3. Growing Awareness and Early Diagnosis

Nationwide campaigns by heart associations, patient advocacy groups, hospitals, and media organizations have significantly improved public understanding of aortic stenosis and heart valve disease.

General practitioners now routinely screen older adults using:

Echocardiography

Advanced imaging tools

AI-assisted diagnostic platforms

The earlier detection of valve disorders enables timely referrals for TAVR before complications escalate. This early-intervention culture is driving procedure volumes and contributing to better long-term patient outcomes.

Market Challenges

Despite rapid growth, Japan’s TAVR market faces notable challenges.

1. High Procedure and Device Costs

TAVR remains considerably more expensive than traditional valve surgery. With the need for:

Hybrid operating suites

State-of-the-art imaging technologies

High-priced transcatheter valve systems

Even under national insurance coverage, financial pressures remain a challenge—particularly for smaller hospitals outside major metropolitan centers.

These cost barriers create uneven access, with most TAVR activity concentrated in urban teaching hospitals.

2. Limited Skilled Workforce in Regional Areas

While major cities boast highly trained cardiologists and surgeons, regional Japan faces persistent shortages in:

Interventional cardiologists

Imaging specialists

TAVR support nurses and technicians

Training the next generation requires years of education and hands-on practice. This gap slows the expansion of TAVR services in rural and semi-urban areas where elderly populations are often the highest.

Japan's aging physician population further complicates succession planning in advanced cardiovascular care.

Regional Analysis of the Japan TAVR Market

Japan’s TAVR market is heavily concentrated in major metropolitan regions, where access to advanced cardiac centers is highest.

Tokyo: The National Leader in TAVR Innovation

Tokyo represents the most advanced and fastest-growing TAVR market in the country.

Factors driving Tokyo’s dominance:

Highest concentration of hybrid operating rooms

Premier academic institutions conducting clinical trials

Large pool of TAVR-trained interventional cardiologists

Early access to next-generation self-expanding and balloon-expandable valves

Tokyo sets the national benchmark for procedural safety, innovation adoption, and clinical outcomes. Most early device launches and pilot programs begin here before nationwide rollouts.

Kansai Region: Rising Research and Training Hub

Cities such as Osaka, Kobe, and Kyoto form Japan’s second-largest TAVR cluster.

Kansai’s market strength stems from:

University-led clinical testing and early feasibility studies

Widespread availability of advanced imaging technologies

Collaborative training programs between hospitals and device companies

While adoption is slightly lower than Tokyo, Kansai is rapidly emerging as a major secondary hub for TAVR expansion.

Aichi Prefecture: Growing Demand Fueled by Aging Population

Home to Nagoya, Aichi Prefecture is experiencing robust growth in minimally invasive cardiac procedures.

Contributing factors include:

Established cardiac care centers with strong technological readiness

High-density elderly population

Growing awareness of valve disorders

Early implementation of innovative valve systems through industry partnerships

Aichi’s steady increase in TAVR adoption is positioning it as a strong growth region over the forecast period.

Market Segmentations (Renub Research)

By Type

Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter Mitral Valve Replacement (TMVR)

Transcatheter Pulmonary Valve Replacement (TPVR)

By Material

Mechanical Valves

Biological Valves

By End User

Hospitals

Ambulatory Surgical Centers

Others

By City

Tokyo

Kansai

Aichi

Kanagawa

Saitama

Hyogo

Chiba

Hokkaido

Fukuoka

Shizuoka

Competitive Landscape

The Japan TAVR market is dominated by global leaders in structural heart technologies alongside rapidly advancing Asia-based manufacturers.

Key Companies Covered

Edwards Lifesciences

Abbott Laboratories

Medtronic Plc

LIVANOVA PLC

Boston Scientific Corporation

Artivion, Inc.

MicroPort Scientific Corporation

Venus Medtech (Hangzhou) Inc.

Each company analysis includes:

Overview

Key People

Revenue Analysis

SWOT Analysis

Recent Developments

Edwards Lifesciences and Medtronic remain the market frontrunners due to strong clinical data and physician familiarity, but Asian firms like MicroPort and Venus Medtech are rapidly rising with competitively priced, technologically enhanced valve systems.

Final Thoughts

Japan’s Transcatheter Heart Valve Replacement Market is entering a pivotal growth phase. With an aging population, high prevalence of valve disease, world-leading healthcare infrastructure, and accelerating device innovation, the country is poised to remain one of Asia’s most important TAVR markets through 2033.

Despite challenges such as high costs and workforce limitations, continuous regulatory support, physician training, and technological breakthroughs are paving the way for broader adoption and improved patient outcomes.

As minimally invasive cardiac therapies continue to reshape cardiovascular care, Japan is emerging as a powerhouse of innovation, research, and clinical excellence in the global TAVR landscape.

healthindustrypsychology

About the Creator

Ben Tom

Ben Tom is a seasoned content writer with 12+ years of experience creating SEO-friendly blogs, web copy, and marketing content that boosts visibility, engages audiences, and drives results.

Reader insights

Be the first to share your insights about this piece.

How does it work?

Add your insights

Comments

There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment

    Find us on social media

    Miscellaneous links

    • Explore
    • Contact
    • Privacy Policy
    • Terms of Use
    • Support

    © 2026 Creatd, Inc. All Rights Reserved.